Methods	Methods of randomisation and allocation concealment were not described
Participants	70 patients undergoing elective coronary artery bypass graft (CABG) surgery were randomised to one of three groups Desmopressin (DDAVP) group: n = 22; mean age (+/−SD) = 63.6 (8.4) years. Desmopressin (DDAVP) + Placebo group: n = 21; mean age (+/−SD) = 59.8 (5.5) years Placebo group: n = 22; mean age (+/−SD) = 61.7 (7.0) years NB: Data for gender was not reported. Two patients were excluded prior to randomisation for haemodynamic instability and three patients were excluded after randomisation for mediastinal exploration secondary to surgical bleeding
Interventions	DDAVP group received 0.3 ug/kg of DDAVP intravenously immediately after protamine reversal of heparin and 12 hours later in the Intensive Care Unit (ICU). DDAVP + placebo group received 0.3 ug/kg of DDAVP after protamine reversal of heparin and saline (placebo) 12 hours later in ICU. Placebo group received saline IV after protamine reversal of heparin and 12 hours later in the ICU.
Outcomes	Number of patients transfused allogeneic blood (n) Amount of allogeneic blood transfused (ml) Number of patients transfused fresh frozen plasma (n) Number of patients transfused platelets (n) Blood loss (ml) Myocardial infarction (n) Deep venous thrombosis (n) Stroke (n)
Notes	Quality assessment score (Schulz criteria): 3/7 Transfusion protocol used.
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Method of randomisation was not described.
Allocation concealment?	Unclear	B - Unclear
Blinding? All outcomes	Yes	Double blind.